TY - JOUR
T1 - Cutting edge
T2 - Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
AU - Matchett, William E.
AU - Joag, Vineet
AU - Stolley, J. Michael
AU - Shepherd, Frances K.
AU - Quarnstrom, Clare F.
AU - Mickelson, Clayton K.
AU - Wijeyesinghe, Sathi
AU - Soerens, Andrew G.
AU - Becker, Samuel
AU - Thiede, Joshua M.
AU - Weyu, Eyob
AU - O'Flanagan, Stephen D.
AU - Walter, Jennifer A.
AU - Vu, Michelle N.
AU - Menachery, Vineet D.
AU - Bold, Tyler D.
AU - Vezys, Vaiva
AU - Jenkins, Marc K.
AU - Langlois, Ryan A.
AU - Masopust, David
N1 - Publisher Copyright:
Copyright © 2021 by The American Association of Immunologists, Inc.
PY - 2021/7/15
Y1 - 2021/7/15
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=85111142331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111142331&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.2100421
DO - 10.4049/jimmunol.2100421
M3 - Article
C2 - 34193597
AN - SCOPUS:85111142331
SN - 0022-1767
VL - 207
SP - 376
EP - 379
JO - Journal of Immunology
JF - Journal of Immunology
IS - 2
ER -
